RETRACTED ARTICLE: Didox (A Novel Ribonucleotide Reductase Inhibitor) Overcomes bcl-2 Mediated Radiation Resistance in Prostate Cancer Cell Line PC-3

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Cancer Biology & Therapy

• Publication date

  2002-08-13

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.4161/cbt.1.5.174PMID 12496485
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Mutations within the tumour suppressor gene p53 are not confined to a late event in prostate cancer progression. a review of the evidence.

  2001cited by this paper
• Cancer statistics, 2000

  2000cited by this paper
• Low dose fractionated radiation enhances the radiosensitization effect of paclitaxel in colorectal tumor cells with mutant p53

  2000cited by this paper
• Genetic alterations in human prostate cancer: a review of current literature.

  2000cited by this paper
• Low dose fractionated radiation enhances the radiosensitization effect of paclitaxel in colorectal tumor cells with mutant p53.

  2000cited by this paper
• The role of cell cycle progression in radiosensitization by 2',2'-difluoro-2'-deoxycytidine.

  2000cited by this paper
• Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense Bcl-2 oligodeoxynucleotides.

  2000cited by this paper
• Mutually exclusive expression patterns of Bcl-2 and Par-4 in human prostate tumors consistent with down-regulation of Bcl-2 by Par-4

  1999cited by this paper
• In Vivo and In Vitro Comparison of the Short‐Term Hematopoietic Toxicity Between Hydroxyurea and Trimidox or Didox, Novel Ribonucleotide Reductase Inhibitors with Potential Anti‐HIV‐1 Activity

  1999cited by this paper
• Tumor Necrosis Factor Induces Bcl-2 and Bcl-x Expression through NFκB Activation in Primary Hippocampal Neurons*

  1999cited by this paper
• Induction of growth inhibition and apoptosis in pancreatic cancer cells by auristatin-PE and gemcitabine.

  1999cited by this paper
• The Bcl-2 protein family: arbiters of cell survival.

  1998cited by this paper
• bcl-2/bax ratio as a predictive marker for therapeutic response to radiotherapy in patients with prostate cancer.

  1998cited by this paper
• Bcl-Xshort is elevated following severe global ischemia in rat brains.

  1997cited by this paper
• Bcl-2 and Bcl-XL can differentially block chemotherapy-induced cell death.

  1997cited by this paper
• Early Growth Response-1-dependent Apoptosis Is Mediated by p53*

  1997cited by this paper
• Taxol induces bcl-2 phosphorylation and death of prostate cancer cells.

  1996cited by this paper
• EGR-1 Induction Is Required for Maximal Radiosensitivity in A375-C6 Melanoma Cells*

  1996cited by this paper
• Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo.

  1995cited by this paper
• DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2.

  1994cited by this paper
• Detection of the apoptosis-suppressing oncoprotein bc1-2 in hormone-refractory human prostate cancers.

  1993cited by this paper
• Hormone-regulated apoptosis results from reentry of differentiated prostate cells onto a defective cell cycle.

  1992cited by this paper
• Experience with hydroxyurea as a radiosensitizer in carcinoma of the cervix.

  1992cited by this paper
• Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer.

  1992cited by this paper
• BCL2 protein is topographically restricted in tissues characterized by apoptotic cell death.

  1991cited by this paper
• Ionizing radiation induces expression and binding activity of the nuclear factor kappa B.

  1991cited by this paper
• Cancer statistics

  1989cited by this paper
• Inhibition of nucleoside diphosphate reductase by hydroxybenzohydroxamic acid derivatives.

  1985cited by this paper
• New ribonucleotide reductase inhibitors with antineoplastic activity.

  1979cited by this paper
• A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

  1976cited by this paper
• Chromosome aberration and mitotic death in x-irradiated HeLa cells.

  1968cited by this paper

• Investigational CXCR4 inhibitors in early phase development for the treatment of hematological malignancies

  2024cites this paper
• Inhibitors of the Cancer Target Ribonucleotide Reductase, Past and Present

  2022cites this paper
• Drivers of Radioresistance in Prostate Cancer

  2022cites this paper
• Anti-proliferative effects of the combination of Sulfamethoxazole and Quercetin via caspase3 and NFkB gene regulation: an in vitro and in vivo study

  2021cites this paper
• The Antitumor Didox Acts as an Iron Chelator in Hepatocellular Carcinoma Cells

  2019influential citation
• Vicenin‐2 acts as a radiosensitizer of the non‐small cell lung cancer by lowering Akt expression

  2018cites this paper
• Solitary Plasmacytomas and Soft-Tissue Involvement in Multiple Myeloma

  2018cites this paper
• CXCR4-Directed Endoradiotherapy as New Treatment Option in Advanced Multiple Myeloma

  2018cites this paper
• Clinical pharmacology and clinical trials of ribonucleotide reductase inhibitors: is it a viable cancer therapy?

  2017cites this paper
• Acute neuroinflammation induces AIS structural plasticity in a NOX2-dependent manner

  2017cites this paper
• Didox (3,4-dihydroxybenzohydroxamic acid) suppresses IgE-mediated mast cell activation through attenuation of NFκB and AP-1 transcription.

  2017cites this paper
• Newly established myeloma-derived stromal cell line MSP-1 supports multiple myeloma proliferation, migration, and adhesion and induces drug resistance more than normal-derived stroma

  2016cites this paper
• Didox and resveratrol sensitize colorectal cancer cells to doxorubicin via activating apoptosis and ameliorating P-glycoprotein activity

  2016cites this paper
• Resolution of Inflammation Rescues Axon Initial Segment Disruption

  2016cites this paper
• Bone Disease in Multiple Myeloma.

  2016cites this paper
• Citrullination of histone H3 drives IL-6 production by bone marrow mesenchymal stem cells in MGUS and multiple myeloma

  2016cites this paper
• Integrative Development of a TLR8 Agonist for Ovarian Cancer Chemoimmunotherapy

  2016cites this paper
• Highly Expressed Integrin-α8 Induces Epithelial to Mesenchymal Transition-Like Features in Multiple Myeloma with Early Relapse

  2016cites this paper
• Compromised axon initial segment integrity in EAE is preceded by microglial reactivity and contact

  2016cites this paper
• Chemokines and Bone

  2015cites this paper
• Pathogenesis beyond the cancer clone(s) in multiple myeloma.

  2015cites this paper
• Targeting Ribonucleotide Reductase M2 and NF-κB Activation with Didox to Circumvent Tamoxifen Resistance in Breast Cancer

  2015cites this paper
• Adipocyte-derived players in hematologic tumors: useful novel targets?

  2015cites this paper
• The chemomodulatory effects of resveratrol and didox on herceptin cytotoxicity in breast cancer cell lines

  2015cites this paper
• Emerging roles of radioresistance in prostate cancer metastasis and radiation therapy

  2014cites this paper
• Suppression of essential pro-inflammatory signaling pathways by natural agents for the therapy of Multiple Myeloma

  2014cites this paper
• Exosomes Secreted by Human Placenta Carry Functional Fas Ligand and TRAIL Molecules and Convey Apoptosis in Activated Immune Cells, Suggesting Exosome-Mediated Immune Privilege of the Fetus

  2013cites this paper
• Complications and Special Presentations of Plasma Cell Myeloma

  2013cites this paper
• Fatty acid synthase causes drug resistance by inhibiting TNF-α and ceramide production[S]

  2013cites this paper
• Anti-Notch treatment prevents multiple myeloma cells localization to the bone marrow via the chemokine system CXCR4/SDF-1

  2013cites this paper
• Radiosensitization in prostate cancer: mechanisms and targets

  2013cites this paper
• Hydroxamates as Ribonucleotide Reductase Inhibitors

  2013cites this paper
• Radical scavengers as ribonucleotide reductase inhibitors.

  2013cites this paper
• P-selectin glycoprotein ligand regulates the interaction of multiple myeloma cells with the bone marrow microenvironment.

  2012cites this paper
• Mechanisms Linking Obesity and Leukemia Prognosis

  2012cites this paper
• A programmable microfluidic cell array for combinatorial drug screening.

  2012cites this paper
• Glucocorticoid receptor antagonist sensitizes TRAIL-induced apoptosis in renal carcinoma cells through up-regulation of DR5 and down-regulation of c-FLIP(L) and Bcl-2

  2012cites this paper
• Calyculin A causes sensitization to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by ROS-mediated down-regulation of cellular FLICE-inhibiting protein (c-FLIP) and by enhancing death receptor 4 mRNA stabilization

  2012cites this paper
• Tumor cell-selective apoptosis induction through targeting of KV10.1 via bifunctional TRAIL antibody

  2011cites this paper
• Synergistic anti-cancer effects via co-delivery of TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) and doxorubicin using micellar nanoparticles.

  2011cites this paper
• Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach.

  2011cites this paper
• Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features.

  2011cites this paper
• Cathepsin E enhances anticancer activity of doxorubicin on human prostate cancer cells showing resistance to TRAIL-mediated apoptosis

  2010cites this paper
• Bcl‐XL and STAT3 mediate malignant actions of γ‐irradiation in lung cancer cells

  2010cites this paper
• Radiosensitization of hormone-refractory prostate cancer cells by gossypol treatment.

  2010cites this paper
• The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody.

  2010cites this paper
• The CXCR4 Antagonist AMD3100 Has Dual Effects on Survival and Proliferation of Myeloma Cells In Vitro

  2010cites this paper
• Bone marrow stromal cells from multiple myeloma patients uniquely induce bortezomib resistant NF-κB activity in myeloma cells

  2010cites this paper
• Glycogen Synthase Kinase-3 regulates multiple myeloma cell growth and bortezomib-induced cell death

  2010cites this paper
• Bone marrow microenvironment in myelomagenesis: its potential role in early diagnosis

  2010cites this paper
• Didox modulates reactive oxygen species production and inflammatory events induced by lipopolysaccharide (LPS) and aryl hydrocarbon receptor (AHR) ligands in raw 264.7 murine macrophages

  2009cites this paper
• The novel Akt inhibitor Palomid 529 (P529) enhances the effect of radiotherapy in prostate cancer

  2009cites this paper
• Dexamethasone and hypoxia upregulate CXCR4 expression in myeloma cells

  2009cites this paper
• RhoA and Rac1 GTPases play major and differential roles in stromal cell-derived factor-1-induced cell adhesion and chemotaxis in multiple myeloma.

  2009cites this paper
• Targeting the DNA damage response in cancer.

  2009cites this paper
• CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy.

  2009cites this paper
• Ribonucleotide Reductase Inhibitors for Restenosis

  2008cites this paper
• Tumour-immune cell interactions modulated by chemokines

  2008cites this paper
• Dichloroacetate (DCA) sensitizes both wild‐type and over expressing Bcl‐2 prostate cancer cells in vitro to radiation

  2008cites this paper
• Cell carriers to deliver oncolytic viruses to sites of myeloma tumor growth

  2008cites this paper
• FLICE-Like Inhibitory Protein Blocks Transforming Growth Factor β1–Induced Caspase Activation and Apoptosis in Prostate Epithelial Cells

  2008cites this paper
• Stromal Cell-Derived Factor-1 Promotes Myeloma Cell Growth in Both Autocrine and Paracrine Manners

  2008cites this paper
• RIBONUCLEOTIDE REDUCTASE INHIBITORS FOR RESTENOSIS MASTER ’ S THESIS Presented in Partial Fulfillment of the Requirements for the Degree Master in Science in The Graduate School of The Ohio State University By

  2008cites this paper
• Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets

  2007cites this paper
• Novel resveratrol derivatives induce apoptosis and cause cell cycle arrest in prostate cancer cell lines.

  2007cites this paper
• The Role of the Bone Marrow Microenvironment in the Pathogenesis of Multiple Myeloma

  2007cites this paper
• The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia.

  2007cites this paper
• Common variants in genes that mediate immunity and risk of multiple myeloma

  2007cites this paper
• Selective Inhibition of IκB Kinase Sensitizes Mantle Cell Lymphoma B Cells to TRAIL by Decreasing Cellular FLIP Level1

  2007cites this paper
• Niches Within the Multiple Myeloma Bone Marrow Microenvironment

  2007cites this paper
• Didox, a ribonucleotide reductase inhibitor, induces apoptosis and inhibits DNA repair in multiple myeloma cells

  2006cites this paper
• Chemotherapy pretreatment sensitizes solid tumor‐derived cell lines to Vα24+ NKT cell‐mediated cytotoxicity

  2006cites this paper
• Role of metalloproteinases MMP‐9 and MT1‐MMP in CXCL12‐promoted myeloma cell invasion across basement membranes

  2006cites this paper
• Importance of the bone marrow microenvironment in inducing the angiogenic response in multiple myeloma

  2006cites this paper
• The SDF-1 G > A polymorphism at position 801 plays no role in multiple myeloma but may contribute to an inferior cause-specific survival in chronic lymphocytic leukemia

  2006cites this paper
• Ribonucleotide reductase inhibitors and future drug design.

  2006cites this paper
• RelB regulates manganese superoxide dismutase gene and resistance to ionizing radiation of prostate cancer cells

  2006cites this paper
• Current therapeutic uses of lenalidomide in multiple myeloma

  2006cites this paper
• Identification and validation of novel therapeutic targets for multiple myeloma.

  2005cites this paper
• Ribonucleotide reductase: target therapy for human disease

  2005cites this paper
• SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma.

  2005cites this paper
• Targeting signalling pathways for the treatment of multiple myeloma

  2005cites this paper
• Cisplatin Inactivation of Caspases Inhibits Death Ligand-induced Cell Death in Vitro and Fulminant Liver Damage in Mice*

  2005cites this paper
• Targeted therapy in multiple myeloma.

  2005cites this paper
• Novel therapeutic strategies targeting growth factor signalling cascades in multiple myeloma

  2005cites this paper
• Drug Insight: thalidomide as a treatment for multiple myeloma

  2005cites this paper
• Novel targeted drugs for the treatment of multiple myeloma: from bench to bedside

  2005cites this paper
• Radiosensitization by targeting radioresistance-related genes with protein kinase A inhibitor in radioresistant cancer cells

  2005cites this paper
• Inhibition of Ribonucleotide Reductase Reduces Neointimal Formation following Balloon Injury

  2005cites this paper
• A Potent Small Molecule Inhibitor of Bcl-XL as a Novel Molecular Targeted Therapy for Prostate Cancer

  2005cites this paper
• (-)-Gossypol enhances response to radiation therapy and results in tumor regression of human prostate cancer.

  2005cites this paper
• Inflammatory chemokines: their role in tumor growth and progression

  2004cites this paper
• Curcumin confers radiosensitizing effect in prostate cancer cell line PC-3

  2004cites this paper
• Stable Suppression of the R2 Subunit of Ribonucleotide Reductase by R2-targeted Short Interference RNA Sensitizes p53(–/–) HCT-116 Colon Cancer Cells to DNA-damaging Agents and Ribonucleotide Reductase Inhibitors*

  2004cites this paper
• Sensitization of Cells to TRAIL-induced Apoptosis by Decoy Receptor 3*

  2004cites this paper
• PI3-K/AKT/FKHR and MAPK signaling cascades are redundantly stimulated by a variety of cytokines and contribute independently to proliferation and survival of multiple myeloma cells

  2004cites this paper
• RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine

  2004cites this paper
• Death receptor‐induced cell death in prostate cancer

  2004cites this paper
• An update of novel therapeutic approaches for multiple myeloma

  2004cites this paper
• Rasagenthi lehyam (RL) a novel complementary and alternative medicine for prostate cancer

  2004cites this paper